Harbor Health Care ETF (MEDI) Valuation
MEDI valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 66.4 trailing earnings
- Forward P/E
- 23.9 analyst estimates
- Price / sales
- 3.66
- Price / book
- 9.87
- EV / EBITDA
- 25.7
- Earnings yield
- 1.51% inverse of P/E
- Dividend yield
- 0.29% of the holdings
- Return on equity
- 14.9% combined
- Net margin
- 5.5% combined
- Beta
- 0.73 weighted, vs S&P 500
MEDI valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| MEDI | 66.4 | 23.9 | 3.66 | 9.87 | 0.29% | 14.9% | 5.5% | 29.3% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
MEDI valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 96.8% | 66.4 | 23.9 | 3.66 | 9.87 | 0.29% | 14.9% |
MEDI earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How MEDI weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
MEDI largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 20.53% | 42.2 | 24.4 | 14.1 | 0.55% | 35.78% |
| ASND | Ascendis Pharma A/S | 16.86% | 17.3 | 19.8 | 14.2 | — | 71.83% |
| ARGX | argenx SE | 4.90% | 31.2 | 25.9 | 9.7 | — | 11.54% |
| PCVX | Vaxcyte, Inc. | 3.36% | — | — | — | — | — |
| ISRG | Intuitive Surgical, Inc. | 2.82% | 48.9 | 33.3 | 13.7 | — | 4.25% |
| GH | Guardant Health, Inc. | 2.78% | — | — | 18.0 | — | −4.51% |
| INSM | Insmed Incorporated | 2.72% | — | 97.1 | 18.5 | — | −8.52% |
| RYTM | Rhythm Pharmaceuticals, Inc. | 2.60% | — | 526.3 | 24.7 | — | −6.91% |
| UTHR | United Therapeutics Corporation | 2.40% | 19.1 | 16.4 | 7.2 | — | 9.23% |
| RVMD | Revolution Medicines, Inc. | 2.27% | — | — | 9,035.1 | — | −8.31% |
| NTRA | Natera, Inc. | 2.21% | — | — | 20.9 | — | −0.56% |
| IDXX | IDEXX Laboratories, Inc. | 1.91% | 39.8 | 31.4 | 9.7 | — | 3.53% |
| COR | Cencora | 1.73% | 25.3 | 15.7 | 0.2 | 0.70% | 5.03% |
| ABBV | AbbVie Inc. | 1.73% | 80.6 | 16.4 | 7.8 | 2.42% | 1.58% |
| AAVXF | ABIVAX Société Anonyme | 1.65% | — | — | — | — | — |
| HQY | HealthEquity, Inc. | 1.62% | 33.2 | 19.7 | 5.6 | — | 3.58% |
| HCA | HCA Healthcare, Inc. | 1.52% | 15.4 | 13.9 | 1.3 | 0.68% | 7.24% |
| INDV | Indivior PLC | 1.44% | 11.6 | 9.5 | 2.9 | — | 9.10% |
| PTCT | PTC Therapeutics, Inc. | 1.44% | — | 22.7 | 4.9 | — | −1.16% |
| MCK | McKesson Corporation | 1.44% | 26.9 | 19.7 | 0.3 | 0.37% | 3.92% |
| DHR | Danaher Corporation | 1.39% | 40.8 | 23.8 | 6.4 | 0.70% | 2.50% |
| XENE | Xenon Pharmaceuticals Inc. | 1.19% | — | — | 727.4 | — | −12.40% |
| GKOS | Glaukos Corporation | 1.18% | — | — | 15.9 | — | −1.71% |
| LEGN | Legend Biotech Corporation | 1.13% | — | 27.5 | 2.8 | — | −2.33% |
| UNH | UnitedHealth Group Incorporated | 1.04% | 25.8 | 16.6 | 0.8 | 2.31% | 2.97% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About MEDI valuation
Adding up its 39 holdings with company data, MEDI trades at 66.4 times trailing earnings and 23.9 times analysts' forward estimates, with a price-to-book ratio of 9.87 and a dividend yield of 0.29%. Its earnings yield of 1.51% is 3.82 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 61.2% of the fund and earn 103.8% of its combined profit. Companies that lost money over the past year are 29.3% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 93.3% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: MEDI chart, MEDI performance, MEDI holdings, MEDI dividends.
MEDI valuation FAQ
What is the P/E ratio of MEDI?
Based on its holdings, MEDI has a trailing P/E of 66.4 and a forward P/E of 23.9 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of MEDI?
The trailing earnings yield is 1.51% (1 ÷ P/E) and the forward earnings yield 4.19%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is MEDI more expensive than the S&P 500?
MEDI trades at 66.4 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 23.9 and 19.9.
What is the price-to-book ratio of MEDI?
The holdings of MEDI trade at 9.87 times book value, with a combined return on equity of 14.9%.